Related Experiment Video
Updated: Apr 21, 2026

12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
19.5K
A practical guide to concentrated insulin for pharmacists.
Journal of Pharmacy Practice
|November 7, 2014
Summary
Concentrated U-500 insulin offers a potent option for managing type 1 and type 2 diabetes when other treatments fail. Pharmacists play a key role in educating patients and preventing dosing errors with this high-strength insulin formulation.
Area of Science:
- Endocrinology
- Pharmacology
Background:
- Insulin is crucial for glucose regulation, impacting muscle glucose uptake and hepatic glucose production.
- It also plays a role in correcting abnormal fat, protein, and carbohydrate metabolism.
- Concentrated insulin (U-500) is a higher potency formulation than standard U-100 insulin.
Purpose of the Study:
- To provide a practical guide for pharmacists on using concentrated U-500 insulin.
- To highlight specific concerns and management strategies for U-500 insulin in inpatient and outpatient settings.
- To emphasize patient education for safe and effective use of concentrated insulin.
Main Methods:
- Review of insulin mechanisms of action.
- Discussion of U-500 insulin indications and patient populations.
- Guidance on pharmacist-led patient education and management strategies.
Main Results:
- U-500 insulin is indicated for adults and children with type 1 and type 2 diabetes not achieving glycemic control with standard therapies.
- Unique characteristics of U-500 insulin necessitate comprehensive patient education.
- Pharmacists are essential in identifying suitable patients and guiding safe U-500 insulin use.
Conclusions:
- Concentrated U-500 insulin shares the same mechanism of action as U-100 formulations.
- Pharmacists are well-positioned to manage U-500 insulin therapy, including preventing dosing errors.
- Education on dosing conversions and titration is vital for patients and healthcare professionals.
Related Concept Videos
Insulin Formulations: Types and Delivery
1.2K
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
1.2K
Insulin: Biosynthesis, Chemistry, and Preparation
2.2K
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
2.2K
Production of Pharmaceuticals
84
Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under...
84
Insulin: Dosing Regimen and Adverse Effects
1.3K
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.3K
Dosage Regimens: Designs and Approaches
576
Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
576
IV Infusion to Oral Dosing: Conversion Methods
176
The development of extended-release formulations has facilitated the transition from intravenous to oral medication, offering a more convenient and patient-friendly approach to drug administration. This transition, however, requires careful management to ensure that therapeutic drug levels are maintained, preserving efficacy and avoiding adverse effects. Understanding pharmacokinetic principles and dosage calculations is critical during this process.Pharmacokinetics of the...
176

